IP Library Granted Patent US 9,707,207
Granted Patent B2
US 9,707,207 · App. 13/117,073 · Granted Jul 18, 2017

Method for diagnosing, preventing, and treating neurological diseases

Inventor: Sydney Martin Finegold (Marina del Rey, CA)
Assignee: The United States of America as represented by the Department of Veterans Affairs
A61K31/397A61K31/424A61K31/427A61K31/43A61K31/431A61K45/06C12Q1/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,707,207
App. No.
13/117,073
Granted
Jul 18, 2017
Kind
B2
Abstract

The invention provides for methods of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.

Claims (5)

1. A method of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam and a beta-lactamase inhibitor in an amount effective to treat autism in the patient, thereby treating autism, wherein the beta-lactamase inhibitor is selected from the group consisting of clavulanic acid, tazobactam, sulbactam and LK-157.

2. The method of claim 1 , wherein aztreonam and the beta-lactamase inhibitor are administered concurrently.

3. The method of claim 1 further comprising administering a probiotic and/or a probiotic group.

4. The method of claim 3 , wherein the probiotic and/or a probiotic group is selected from the group consisting of bacteria that competes with Desulfovibrio for nutrients in the intestinal tract and bacteria that inhibits growth of Desulfovibrio in the intestinal tract.

5. The method of claim 4 , wherein a probiotic and/or a probiotic group is selected from the group consisting of Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides distasonis, Bacteroides fragilis, Bifidobacterium adolescentis group, Eubacterium aerofaciens, Clostridium ramosum, Escherichia coli, Streptococcus faecalis group, Lactobacillus spp., L. acidophilus , gram-negative anaerobes, enterococci, Bacteroides sp., Parabacteroides, Prevotella, Porphyromonas , gram-positive anaerobic cocci, Clostridium sp., Enterobacteriaceae, E. coli, L. bulgaricus, S. thermophilus, Collinsella genus, Bifidobacterium genus, Bifidobacterium longum, Bifidobacterium angulatum, Dialister invisus, Clostridium leptum, Firmicutes, Actinobacteria, Faecalibacterium, Ruminococcus, Eubacterium, Alistipes, Roseburia, Anaerofilum, Streptococcus, Turicibacter, Parabacteroides, Dorea, Veillonella, Akkermansia, Sporobacter, Ethanoligenens, Papillibacter, Holdemania, Weissella, Dialister, Pseudoramibacter, Streptococcus, Anaerovorax, Lactococcus, Leuconostoc, Ethanoligenens, Helcococcus, Alkaliphilus, Clostridium aldenense, Clostridium methylpentosum, Eubacterium ruminantium, Phascolarctobacterium faecium, Alistipes onderdonkii, Bacteroides caccae and mixtures thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2012
From: FINEGOLD, SYDNEY M
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 027565/0398 →
Continuity (2)
Provisional Application 61275714 · May 26, 2010
Related Publication 20120252775A1 · Oct 4, 2012